Compositions and methods for treating diseases

Patent metadata

Field	Value
Publication number	US-2023391826-A1
Application number	US-202318172116-A
Country	US
Kind code	A1
Filing date	Aug 28, 2023
Priority date	Sep 14, 2020
Publication date	Dec 7, 2023
Grant date	—

Abstract

Disclosed herein are methods and compositions engineered to modulate ephrin type-A receptor 2 (EphA2), including novel compositions comprising one or more dimeric peptide units that binds to a EphA2, wherein the dimeric peptide comprises two or more homologous sequences or fragments thereof, wherein the two or more homologous sequences or fragments thereof, individually, comprise one or more binding sites for the EphA2 with unexpectedly high specificity and binding affinity. The compositions described herein can be attenuated to treat subjects suffering from diseases and/or conditions.

First claim

1 - 105 . (canceled)

106 . A composition comprising a peptide comprising at least a first subunit and a second subunit, wherein said first subunit comprises X1-W-L-A-Y-P-D-S-V-P-Y-X2, and wherein said second subunit comprises X1-W-L-A-Y-P-D-S-V-P-Y-X2, wherein
X1 is A, βAlanine, a first spacer, C, azido-lysine (K N3 ), propargylglycine (Pra), or any combination thereof; and X2 is R, a second spacer, P-K, C, K, or any combination thereof.

107 . The composition of claim 106 , wherein said C is carbamidomethyl-cysteine (C cam ).

108 . The composition of claim 106 , wherein a C-terminus of said first subset, said second subset, or both is amidated.

109 . The composition of claim 106 , wherein said first spacer and said second spacer comprise one or more amino acids.

110 . The composition of claim 106 , wherein said first spacer and said second spacer comprise a glycine.

111 . The composition of claim 106 , wherein said first spacer and said second spacer comprise a glycine and a serine.

112 . The composition of claim 106 , wherein said first subunit and said second subunit are homologous.

113 . The composition of claim 106 , wherein an N-terminus of said first subunit or said second subunit, or a C-terminus of said first subunit or said second subunit, or any combination thereof, comprises biotin.

114 . The composition of claim 106 , wherein said first subunit or said second subunit further comprises acetylation of a Lys14 side chain.

115 . The composition of claim 106 , wherein said composition comprises any one of the peptides represented by SEQ ID NOs: 1-8.

116 . A pharmaceutical composition comprising
the composition of claim 106 ; and one or more pharmaceutically acceptable excipients.

117 . A method of treating a disease or condition in a subject in need thereof, comprising administering the pharmaceutical composition of claim 116 , to said subject.

118 . The method of claim 117 , further comprising administering a half-life extending molecule to said subject.

119 . The method of claim 117 , wherein said disease or condition is a parasitic infection.

120 . The method of claim 117 , wherein said disease or condition is pathological forms of angiogenesis.

121 . The method of claim 117 , wherein said disease or condition is an inflammatory disease.

122 . The method of claim 121 , wherein said inflammatory disease is atherosclerosis, diabetes, arthritis, psoriasis, multiple sclerosis, lupus, inflammatory bowel disease, Addison's disease, Grave's disease, Sjogren's syndrome, Hashimoto's thyroiditis, Myasthenia gravis, Autoimmune vasculitis, Pernicious anemia, graft-versus-host disease, or Celiac disease.

123 . The method of claim 117 , wherein said disease or condition is cancer.

124 . The method of claim 123 , wherein said cancer is prostate cancer, castration resistant prostate cancer, neuroendocrine prostate cancer, transitional cell prostate cancer, squamous cell prostate cancer, or small cell prostate cancer.

125 . A method of preventing or reversing the onset of a subset of a disease or condition in a subject suffering from a disease or condition, comprising administering the pharmaceutical composition of claim 116 to said subject.

Assignees

• Sanford Burnham Prebys Medical Discovery Inst

Inventors

• Pasquale Elena B
• Lechtenberg Bernhard C

Classifications

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P29/00 Primary

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P33/00

  Antiparasitic agents · CPC title